Vaxart (VXRT) Global BioInnovation Forum 2026 summary

Innovation in vaccine delivery

• Focus on oral recombinant pill vaccines to replace traditional injections, aiming for greater convenience and accessibility.

• Technology leverages mucosal immunology to induce IgA antibodies at pathogen entry points, enhancing cross-protection.

• Platform allows rapid adaptation to new pathogens by inserting genes of interest into a stable adenoviral vector.

• Tablets are thermostable, easy to distribute, and eliminate the need for cold chain logistics and medical waste.

• Oral vaccines can be self-administered, increasing global access and potentially improving vaccination rates.

Clinical and preclinical data highlights

• Preclinical studies in animal models demonstrated reduced transmission and cross-protection against multiple strains.

• Norovirus challenge studies showed prevention of infection and robust immune responses in diverse populations, including lactating mothers and the elderly.

• COVID-19 oral vaccine produced strong mucosal and T-cell responses in phase 1 trials.

• Influenza oral vaccine reduced symptomatic infection more than a leading injected vaccine in head-to-head studies.

• Safety profile across nearly 1,200 subjects is comparable to placebo, with no injection site reactions.

Forward-looking statements and upcoming milestones

• Top-line results from a 400-person COVID-19 trial comparing oral and mRNA vaccines expected in Q1 2026.

• Larger 5,000-subject COVID-19 trial results anticipated in late 2026.

• Phase 2b norovirus vaccine study could begin as early as 2026, following strong head-to-head data.

• Ongoing development of seasonal and avian influenza programs, leveraging rapid platform adaptability.

• Emphasis on the potential for the oral platform to revolutionize vaccine distribution and acceptance.